ZVSA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases...

Stats
Today's Volume	95 722.00
Average Volume	413 479
Market Cap	3.75M
EPS	$0 ( 2024-05-17 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.0410 (0.91%)

Insider Trading

Date	Person	Action	Amount	type
2023-05-10	Incon Co., Ltd.	Buy	0
2023-01-26	Guzman Pablo A.	Buy	100 000	Stock Options (right to buy)
2022-12-12	Guzman Pablo A.	Sell	9 015	Warrant (Right to Buy)
2023-01-26	Guzman Pablo A.	Sell	0	Common Stock
2023-01-05	Sapirstein James	Buy	0

INSIDER POWER
99.68
Last 73 transactions
Buy: 5 985 759 \| Sell: 1 615 903

Volume Correlation

Long: 0.24 (neutral)

Short: -0.60 (weak negative)

Signal:(41.906) Neutral

ZyVersa Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

ZyVersa Therapeutics, Correlation - Currency/Commodity

-0.76
( moderate negative )

-0.32
( neutral )

0.00
( neutral )

-0.91
( very strong negative )

0.54
( weak )

0.79
( moderate )

ZyVersa Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-10 400.00 (0.00 %)
EPS:	$-1 008.15

FY	2023
Revenue:	$0
Gross Profit:	$-10 400.00 (0.00 %)
EPS:	$-1 008.15

FY	2022
Revenue:	$0
Gross Profit:	$-10 400.00 (0.00 %)
EPS:	$-2 925.42

FY	2021
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.890

Financial Reports:

No articles found.

ZyVersa Therapeutics, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

ZyVersa Therapeutics,

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.